Thaddeus Beck

1.6k total citations · 1 hit paper
21 papers, 1.1k citations indexed

About

Thaddeus Beck is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Thaddeus Beck has authored 21 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Thaddeus Beck's work include Lung Cancer Research Studies (7 papers), Advanced Breast Cancer Therapies (5 papers) and HER2/EGFR in Cancer Research (5 papers). Thaddeus Beck is often cited by papers focused on Lung Cancer Research Studies (7 papers), Advanced Breast Cancer Therapies (5 papers) and HER2/EGFR in Cancer Research (5 papers). Thaddeus Beck collaborates with scholars based in United States, Spain and France. Thaddeus Beck's co-authors include Alan Sandler, Hariharan Subramanian, Troy H. Guthrie, Mark E. Morrison, Lawrence H. Einhorn, Corey J. Langer, Rafat Ansari, Michael Byrne, Nasser H. Hanna and Peter Ellis and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Thaddeus Beck

21 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

2006 500 citations Nasser H. Hanna, Paul A. Bunn et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thaddeus Beck United States	9	885	460	433	386	208	21	1.1k
Joseph Montecalvo United States	12	682 0.8×	757 1.6×	330 0.8×	318 0.8×	180 0.9×	28	1.2k
Monika Serke Germany	15	688 0.8×	758 1.6×	129 0.3×	194 0.5×	104 0.5×	71	1.1k
Jesse W. Keller United States	8	857 1.0×	372 0.8×	171 0.4×	222 0.6×	357 1.7×	15	1.0k
Satoru Kitazono Japan	23	1.0k 1.1×	833 1.8×	125 0.3×	349 0.9×	252 1.2×	92	1.5k
Tina E. Wood United States	7	900 1.0×	218 0.5×	188 0.4×	266 0.7×	331 1.6×	12	1.1k
Andrzej Szawłowski Poland	8	602 0.7×	266 0.6×	141 0.3×	211 0.5×	226 1.1×	21	836
Haiqing Ma China	17	425 0.5×	211 0.5×	155 0.4×	511 1.3×	321 1.5×	27	965
Zachary R. Chalmers United States	15	584 0.7×	580 1.3×	148 0.3×	649 1.7×	349 1.7×	35	1.4k
Xingya Li China	18	613 0.7×	533 1.2×	88 0.2×	360 0.9×	245 1.2×	77	1.1k
Michael J. Swartz United States	12	975 1.1×	321 0.7×	287 0.7×	381 1.0×	283 1.4×	13	1.2k

Countries citing papers authored by Thaddeus Beck

Since Specialization

Citations

This map shows the geographic impact of Thaddeus Beck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thaddeus Beck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thaddeus Beck more than expected).

Fields of papers citing papers by Thaddeus Beck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thaddeus Beck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thaddeus Beck. The network helps show where Thaddeus Beck may publish in the future.

Co-authorship network of co-authors of Thaddeus Beck

This figure shows the co-authorship network connecting the top 25 collaborators of Thaddeus Beck. A scholar is included among the top collaborators of Thaddeus Beck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thaddeus Beck. Thaddeus Beck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Michel, Loren S., Antonio Jimeno, Ammar Sukari, et al.. (2023). 859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial. Annals of Oncology. 34. S558–S558. 8 indexed citations

Beck, Thaddeus, David Richards, Richy Agajanian, et al.. (2021). MO01.40 Trilaciclib has Myelopreservation Benefits in Patients with Small Cell Lung Cancer Treated with Chemotherapy, Irrespective of Age. Journal of Thoracic Oncology. 16(1). S32–S33. 1 indexed citations

Janni, Wolfgang, Emilio Alba, Thomas Bachelot, et al.. (2018). First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. Breast Cancer Research and Treatment. 169(3). 469–479. 35 indexed citations

Горбунова, В. А., Thaddeus Beck, Ralf‐Dieter Hofheinz, et al.. (2018). Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.. Journal of Clinical Oncology. 36(15_suppl). 3543–3543. 1 indexed citations

Beatty, Gregory L., Safi Shahda, Thaddeus Beck, et al.. (2018). A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors. The Oncologist. 24(1). 14–e10. 36 indexed citations

Gettinger, Scott, Thaddeus Beck, Xinyun Yang, et al.. (2018). CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. Annals of Oncology. 29. viii544–viii545. 2 indexed citations

Rodón, Jordi, Giuseppe Curigliano, Jean‐Pierre Delord, et al.. (2018). A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget. 9(60). 31709–31718. 39 indexed citations

Garrido, Pilar, Jonathan W. Goldman, Karen Kelly, et al.. (2017). Efficacy and safety of abemaciclib combined with either LY3023414 or pembrolizumab in stage IV NSCLC. Annals of Oncology. 28. v487–v487. 1 indexed citations

Daniel, Davey B., Charles M. Rudin, L. Hart, et al.. (2017). Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Annals of Oncology. 28. v540–v540. 15 indexed citations

10.

Janni, Wolfgang, Emilio Alba, Thomas Bachelot, et al.. (2017). Duration of response and tumor shrinkage with first-line ribociclib + letrozole in postmenopausal women with HR+, HER2– ABC. Annals of Oncology. 28. v78–v78. 1 indexed citations

11.

Beeram, Muralidhar, Thaddeus Beck, DA Richards, et al.. (2016). Abstract P4-13-25: Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer. Cancer Research. 76(4_Supplement). P4–13. 6 indexed citations

12.

Quoix, Élisabeth, Lecia V. Sequist, John Nemunaitis, et al.. (2014). TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study. Journal for ImmunoTherapy of Cancer. 2(Suppl 3). O12–O12. 4 indexed citations

13.

Beck, Thaddeus, et al.. (2013). Long-Term Management of a Patient with Well-Differentiated Pulmonary Neuroendocrine Carcinoma: A Case Report. Case Reports in Oncology. 6(1). 209–215. 3 indexed citations

14.

Harbeck, Nadia, Manfred Schmitt, Christoph Meisner, et al.. (2013). Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. European Journal of Cancer. 49(8). 1825–1835. 127 indexed citations

15.

Patel, Jyoti D., Mark A. Socinski, Edward B. Garon, et al.. (2013). PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 31(34). 4349–4357. 281 indexed citations

16.

Kuske, Robert R., et al.. (2013). Utility of a Novel 3-D Marker in Postoperative Treatment Planning for Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. 87(2). S244–S245. 2 indexed citations

17.

Borson, R., Graydon Harker, James A. Reeves, et al.. (2012). Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer. 12(5). 322–330. 7 indexed citations

18.

Brufsky, Adam, Karen Hoelzer, Thaddeus Beck, et al.. (2011). A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer. Clinical Breast Cancer. 11(4). 211–220. 25 indexed citations

19.

Brufsky, Adam, Graydon Harker, Thaddeus Beck, et al.. (2009). Bone-specific alkaline phosphatase (BSAP) and serum N-telopeptide (sNTX) as predictors of bone loss in postmenopausal women with early breast cancer receiving letrozole as adjuvant therapy: a 5-year study (Z-FAST).. Cancer Research. 69(2_Supplement). 2067–2067. 2 indexed citations

20.

Hanna, Nasser H., Paul A. Bunn, Corey J. Langer, et al.. (2006). Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer. Journal of Clinical Oncology. 24(13). 2038–2043. 500 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact